news
New ‘smart’ cell therapies show promise in solid tumours
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
List view / Grid view
Biologics
article
Drug Target Review – Issue 4 2020
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
article
Developing nanobodies and sybodies to combat COVID-19
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
news
Researchers develop novel class of cancer immunotherapy
The scientists developed a therapy which uses nanobiologics to train the innate immune system to recognise and combat cancer cells.
news
Novel Alzheimer’s vaccine shows promise in murine models
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
article
Expert view: Where are you seeing changes in the flow cytometry market?
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules
Biologics are becoming increasingly important for the treatment of a wide variety of diseases, with more biologics receiving regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and entering the clinic every year.
news
Protective antibodies identified for rare polio-like disease in children
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
news
Experimental formulation could be future for fast-acting insulin
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
whitepaper
Whitepaper: Addressing the challenges in biologics discovery with advanced flow cytometry
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.
whitepaper
Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
article
Expert view: High-throughput analytics for smarter cell-line development
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
